Pioglitazone and insulin glargine are equally effective in achieving glycemic control in secondary drug failure of type 2 diabetes but the mechanisms of actions are different.
The present study was undertaken to assess differences in how insulin glargine vs. pioglitazone affect: * Beta-cell function as measured by proinsulin/insulin, homeostasis model assessment for insulin secretion (HOMA β-cell) and glucagon stimulated C-peptide test * Insulin sensitivity as measured by adiponectin, homeostasis model assessment for insulin resistance (HOMA-IR) and insulin tolerance test and * Surrogate markers of cardiovascular disease as measured by BNP, NT-pro BNP and plasma lipid profile as add-on therapy in patients with T2D and secondary drug failure. The patients' satisfaction with each treatment was also surveyed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
36
tablet, 30 mg, once daily, 26 weeks
subcutaneous injection, start dose 6-10 units, once daily, 26 weeks
Malmö University Hospital
Malmö, Sweden
Effect of pioglitazone vs. insulin glargine on beta-cell function and insulin sensitivity
Time frame: 26 weeks
Effect of pioglitazone vs. insulin glargine on BNP
Time frame: 26 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.